DETAILS, FICTION AND CLINICAL EFFECTIVENESS OF ABBV-744 IN AML PATIENTS

In Phase C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually ailment progression or the members are unable to tolerate the study drugs.Over-all, our recent work highlights the potential utilization of ARV-825 in combination with TAM. Ev